Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target

Phathom Pharmaceuticals is attractive because VOQUEZNA is the only FDA-approved P-CAB in the U.S. today, giving it a differentiated position in the large second-line, PPI-refractory GERD market where roughly 40% of patients may be inadequately controlled on PPIs. Its clinical profile is compelling, with rapid and durable anti-secretory effects, about 45% 24-hour heartburn-free days in PHALCON-NERD versus 28% for placebo, and strong H. pylori eradication rates, especially in clarithromycin-resistant patients. Fundamentally, the thesis is supported by growing sales from $55MM in 2024 to 2026 guidance of $310–325MM, targeted May 2025 restructuring, and the potential for further upside from access improvement, tegoprazan, and EoE expansion.

Phathom Pharmaceuticals is facing a weak fundamental setup because VOQUEZNA’s 2026 growth has already been slowed by physician access friction, which could delay reacceleration and reduce peak sales expectations if the issue persists. Competitive pressure is also building, as a tegoprazan launch in 2027 could erode share and pricing, while management is not modeling any EoE revenue due to skepticism that the mechanism can fully address inflammation beyond acid suppression. Financial risk is elevated by the $300 million Hercules term loan secured by nearly all assets, including IP, with minimum cash covenants of 20% of principal rising to 35% if performance slips, and a $130 million equity raise at $16 per share signaled dilution amid softer 2026 shares.